Sk n fi

The neuroblastoma cell lines CHLA-15, CHLA-20, CHLA-42, CHLA-90, CHLA-95, CHLA-171, COG-N-426 (Felix), LA-N-5, LA-N-6, NB-1643, NB-EBC1, SK-N-BE(1), SK-N-BE(2), SK-N-FI, SMS-KAN, SMS-KCR, and SMS-LHN were obtained from COG. CHP-134, IMR-32, KELLY, LA-N-1 and SH-SY5Y were obtained from the European Collection of Authenticated Cell Cultures (ECACC). GI-ME-N, NBL-S and NGP were obtained from German Collection of Microorganisms and Cell Cultures (DSMZ) and 293FT was obtained from Thermo Fisher Scientific. CHLA-15, CHLA-20, CHLA-42, CHLA-90, CHLA-95, CHLA-171, COG-N-426 (Felix), NB-1643, NB-EBC1 and NBL-S cells were cultured in IMDM (Gibco, Cat#21980032) supplemented with 20% FBS, 1% insulin-transferrin-selenium (ITS; Gibco, Cat#41400045) and 1% penicillin/streptomycin (PS). CHP-134, GI-ME-N, IMR-32, KELLY, LA-N-1, LA-N-5, LA-N-6, NGP, SK-N-BE(1), SK-N-BE(2), SK-N-FI, SMS-KAN, SMS-KCNR, and SMS-LHN cells were cultured in RPMI 1640 medium (Gibco, Cat#21875091) supplemented with 10% FBS, 1% insulin-transferrin-selenium (ITS) and 1% penicillin/streptomycin (PS). SH-SY5Y and 293FT cells were cultured in DMEM (Gibco, Cat#41966029) supplemented with 10% FBS and 1% PS. Cells were grown at 37 °C in a humidified incubator with 5% CO₂. All cells were mycoplasma-free and subjected to quarterly in-house testing using the EZ-PCR Mycoplasma Detection Kit (Geneflow, Cat#K1-0210).

All commonly used human NB cell lines (SK-N-BE, IMR-32, NMB, CHP-134, GI-M-EN, SK-N-AS, SK-N-FI, SH-SY5Y) were available in our laboratory.2 (link) The cell line mNB-A1 was derived from the transgenic NB mouse model LSL-MYCN;Dbh-iCre.22 (link) The NHO2A cell line was derived from the transgenic TH-MYCN NB model.23 (link) None of the used cell lines are listed in the ICLAC database of misidentified cancer cell lines. All cell lines were cultured in a humidified incubator with 5% CO₂ at 37 °C. Cell lines were cultured in RPMI-1640 medium with 10% fetal bovine serum, 2 mM glutamine, 100 U/mL penicillin and 100 mg/mL streptomycin (all Gibco, Thermo Fisher Scientific, Waltham, Massachusetts, USA). SK-N-FI was cultured in DMEM/F12 medium (Gibco, Thermo Fisher Scientific). mNB-A1 was cultured with the addition of B-27 and N-2 supplements (all Gibco, Thermo Fisher Scientific). All cell lines were negative for mycoplasma contamination. Testing for mycoplasma was performed by PCR on a monthly basis.

SK-N-FI cells were obtained from ATCC (Manassas, VA, USA), and CHLA-90 cells were obtained from the Children's Oncology Group (COG) Cell Culture and Xenograft Repository. Lan-6 and NBL-S were purchased from DSMZ (Braunschweig, Germany). KELLY and SK-N-BE(2) cells were kindly provided by Dr. Olaf Witt and CLB-GA by Dr. Johannes Schulte. Cell lines were validated by the DSMZ using STR profiling. LM-216-J were kindly provided by Dr. Roderick O`Sullivan. CHLA-90 cells were cultured in IMDM (Thermo Fisher, 12,440–053) supplemented with 20% heat-inactivated fetal bovine serum (Gibco, 10,500–064) and 1% Insulin–transferrin–sodium selenite (ITS) media supplement (Sigma Aldrich, I1884). NBL-S were cultured in IMDM with 10% heat-inactivated fetal bovine serum. SK-N-FI were cultured in DMEM (Thermo Fisher, 11,995–065), 10% heat-inactivated fetal bovine serum and 1% non-essential amino acids (Thermo Fisher, 11,140,050). For Lan-6, DMEM was used supplemented with 20% heat-inactivated fetal bovine serum. Kelly, CLB-GA and SK-N-BE(2) cells were cultured in RPMI (Thermo Fisher, 61,870-010) supplemented with 10% heat-inactivated fetal bovine serum. Cells were grown at 37 °C in a humidified atmosphere with 5% CO₂.